The proportion of endometrial tumours associated with Lynch syndrome (PETALS): A prospective cross-sectional study.
<h4>Background</h4>Lynch syndrome (LS) predisposes to endometrial cancer (EC), colorectal cancer, and other cancers through inherited pathogenic variants affecting mismatch-repair (MMR) genes. Diagnosing LS in women with EC can reduce subsequent cancer mortality through colonoscopic surv...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2020-09-01
|
| Series: | PLoS Medicine |
| Online Access: | https://journals.plos.org/plosmedicine/article/file?id=10.1371/journal.pmed.1003263&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850128773645598720 |
|---|---|
| author | Neil A J Ryan Raymond McMahon Simon Tobi Tristan Snowsill Shona Esquibel Andrew J Wallace Sancha Bunstone Naomi Bowers Ioana E Mosneag Sarah J Kitson Helena O'Flynn Neal C Ramchander Vanitha N Sivalingam Ian M Frayling James Bolton Rhona J McVey D Gareth Evans Emma J Crosbie |
| author_facet | Neil A J Ryan Raymond McMahon Simon Tobi Tristan Snowsill Shona Esquibel Andrew J Wallace Sancha Bunstone Naomi Bowers Ioana E Mosneag Sarah J Kitson Helena O'Flynn Neal C Ramchander Vanitha N Sivalingam Ian M Frayling James Bolton Rhona J McVey D Gareth Evans Emma J Crosbie |
| author_sort | Neil A J Ryan |
| collection | DOAJ |
| description | <h4>Background</h4>Lynch syndrome (LS) predisposes to endometrial cancer (EC), colorectal cancer, and other cancers through inherited pathogenic variants affecting mismatch-repair (MMR) genes. Diagnosing LS in women with EC can reduce subsequent cancer mortality through colonoscopic surveillance and aspirin chemoprevention; it also enables cascade testing of relatives. A growing consensus supports LS screening in EC; however, the expected proportion of test positives, and optimal testing strategy is uncertain. Previous studies from insurance-based healthcare systems were limited by narrow selection criteria, failure to apply reference standard tests consistently, and poor conversion to definitive testing. The aim of this study was to establish the prevalence of LS and the diagnostic accuracy of LS testing strategies in an unselected EC population.<h4>Methods and findings</h4>This was a prospective cross-sectional study carried out at a large United Kingdom gynaecological cancer centre between October 2015 and January 2017. Women diagnosed with EC or atypical hyperplasia (AH) were offered LS testing. Tumours underwent MMR immunohistochemistry (IHC), microsatellite instability (MSI), and targeted MLH1-methylation testing. Women <50 years, with strong family histories and/or indicative tumour molecular features, underwent MMR germline sequencing. Somatic MMR sequencing was performed when indicative molecular features were unexplained by LS or MLH1-hypermethylation. The main outcome measures were the prevalence of LS in an unselected EC population and the diagnostic accuracy of clinical and tumour testing strategies for risk stratifying women with EC for MMR germline sequencing. In total, 500 women participated in the study; only 2 (<1%) declined. Germline sequencing was indicated and conducted for 136 and 135 women, respectively. A total of 16/500 women (3.2%, 95% CI 1.8% to 5.1%) had LS, and 11 more (2.2%) had MMR variants of uncertain significance. Restricting testing to age <50 years, indicative family history (revised Bethesda guidelines or Amsterdam II criteria) or endometrioid histology alone would have missed 9/16 (56%), 8/13 (62%) or 9/13 (69%), and 5/16 (31%) cases of LS, respectively. In total 132/500 tumours were MMR deficient by IHC of which 83/132 (63%) had MLH1-hypermethylation, and 16/49 (33%) of the remaining patients had LS (16/132 with MMR deficiency, 12%). MMR-IHC with targeted MLH1-methylation testing was more discriminatory for LS than MSI with targeted methylation testing, with 100% versus 56.3% (16/16 versus 9/16) sensitivity (p = 0.016) and equal 97.5% (468/484) specificity; 64% MSI-H and 73% MMR deficient tumours unexplained by LS or MLH1-hypermethylation had somatic MMR mutations. The main limitation of the study was failure to conduct MMR germline sequencing for the whole study population, which means that the sensitivity and specificity of tumour triage strategies for LS detection may be overestimated, although the risk of LS in women with no clinical or tumour predictors is expected to be extremely low.<h4>Conclusions</h4>In this study, we observed that age, family history, and histology are imprecise clinical correlates of LS-EC. IHC outperformed MSI for tumour triage and reliably identified both germline and somatic MMR mutations. The 3.2% proportion of LS-EC is similar to colorectal cancer, supporting unselected screening of EC for LS. |
| format | Article |
| id | doaj-art-eceb739d88234f0eb12072b08be0941f |
| institution | OA Journals |
| issn | 1549-1277 1549-1676 |
| language | English |
| publishDate | 2020-09-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS Medicine |
| spelling | doaj-art-eceb739d88234f0eb12072b08be0941f2025-08-20T02:33:11ZengPublic Library of Science (PLoS)PLoS Medicine1549-12771549-16762020-09-01179e100326310.1371/journal.pmed.1003263The proportion of endometrial tumours associated with Lynch syndrome (PETALS): A prospective cross-sectional study.Neil A J RyanRaymond McMahonSimon TobiTristan SnowsillShona EsquibelAndrew J WallaceSancha BunstoneNaomi BowersIoana E MosneagSarah J KitsonHelena O'FlynnNeal C RamchanderVanitha N SivalingamIan M FraylingJames BoltonRhona J McVeyD Gareth EvansEmma J Crosbie<h4>Background</h4>Lynch syndrome (LS) predisposes to endometrial cancer (EC), colorectal cancer, and other cancers through inherited pathogenic variants affecting mismatch-repair (MMR) genes. Diagnosing LS in women with EC can reduce subsequent cancer mortality through colonoscopic surveillance and aspirin chemoprevention; it also enables cascade testing of relatives. A growing consensus supports LS screening in EC; however, the expected proportion of test positives, and optimal testing strategy is uncertain. Previous studies from insurance-based healthcare systems were limited by narrow selection criteria, failure to apply reference standard tests consistently, and poor conversion to definitive testing. The aim of this study was to establish the prevalence of LS and the diagnostic accuracy of LS testing strategies in an unselected EC population.<h4>Methods and findings</h4>This was a prospective cross-sectional study carried out at a large United Kingdom gynaecological cancer centre between October 2015 and January 2017. Women diagnosed with EC or atypical hyperplasia (AH) were offered LS testing. Tumours underwent MMR immunohistochemistry (IHC), microsatellite instability (MSI), and targeted MLH1-methylation testing. Women <50 years, with strong family histories and/or indicative tumour molecular features, underwent MMR germline sequencing. Somatic MMR sequencing was performed when indicative molecular features were unexplained by LS or MLH1-hypermethylation. The main outcome measures were the prevalence of LS in an unselected EC population and the diagnostic accuracy of clinical and tumour testing strategies for risk stratifying women with EC for MMR germline sequencing. In total, 500 women participated in the study; only 2 (<1%) declined. Germline sequencing was indicated and conducted for 136 and 135 women, respectively. A total of 16/500 women (3.2%, 95% CI 1.8% to 5.1%) had LS, and 11 more (2.2%) had MMR variants of uncertain significance. Restricting testing to age <50 years, indicative family history (revised Bethesda guidelines or Amsterdam II criteria) or endometrioid histology alone would have missed 9/16 (56%), 8/13 (62%) or 9/13 (69%), and 5/16 (31%) cases of LS, respectively. In total 132/500 tumours were MMR deficient by IHC of which 83/132 (63%) had MLH1-hypermethylation, and 16/49 (33%) of the remaining patients had LS (16/132 with MMR deficiency, 12%). MMR-IHC with targeted MLH1-methylation testing was more discriminatory for LS than MSI with targeted methylation testing, with 100% versus 56.3% (16/16 versus 9/16) sensitivity (p = 0.016) and equal 97.5% (468/484) specificity; 64% MSI-H and 73% MMR deficient tumours unexplained by LS or MLH1-hypermethylation had somatic MMR mutations. The main limitation of the study was failure to conduct MMR germline sequencing for the whole study population, which means that the sensitivity and specificity of tumour triage strategies for LS detection may be overestimated, although the risk of LS in women with no clinical or tumour predictors is expected to be extremely low.<h4>Conclusions</h4>In this study, we observed that age, family history, and histology are imprecise clinical correlates of LS-EC. IHC outperformed MSI for tumour triage and reliably identified both germline and somatic MMR mutations. The 3.2% proportion of LS-EC is similar to colorectal cancer, supporting unselected screening of EC for LS.https://journals.plos.org/plosmedicine/article/file?id=10.1371/journal.pmed.1003263&type=printable |
| spellingShingle | Neil A J Ryan Raymond McMahon Simon Tobi Tristan Snowsill Shona Esquibel Andrew J Wallace Sancha Bunstone Naomi Bowers Ioana E Mosneag Sarah J Kitson Helena O'Flynn Neal C Ramchander Vanitha N Sivalingam Ian M Frayling James Bolton Rhona J McVey D Gareth Evans Emma J Crosbie The proportion of endometrial tumours associated with Lynch syndrome (PETALS): A prospective cross-sectional study. PLoS Medicine |
| title | The proportion of endometrial tumours associated with Lynch syndrome (PETALS): A prospective cross-sectional study. |
| title_full | The proportion of endometrial tumours associated with Lynch syndrome (PETALS): A prospective cross-sectional study. |
| title_fullStr | The proportion of endometrial tumours associated with Lynch syndrome (PETALS): A prospective cross-sectional study. |
| title_full_unstemmed | The proportion of endometrial tumours associated with Lynch syndrome (PETALS): A prospective cross-sectional study. |
| title_short | The proportion of endometrial tumours associated with Lynch syndrome (PETALS): A prospective cross-sectional study. |
| title_sort | proportion of endometrial tumours associated with lynch syndrome petals a prospective cross sectional study |
| url | https://journals.plos.org/plosmedicine/article/file?id=10.1371/journal.pmed.1003263&type=printable |
| work_keys_str_mv | AT neilajryan theproportionofendometrialtumoursassociatedwithlynchsyndromepetalsaprospectivecrosssectionalstudy AT raymondmcmahon theproportionofendometrialtumoursassociatedwithlynchsyndromepetalsaprospectivecrosssectionalstudy AT simontobi theproportionofendometrialtumoursassociatedwithlynchsyndromepetalsaprospectivecrosssectionalstudy AT tristansnowsill theproportionofendometrialtumoursassociatedwithlynchsyndromepetalsaprospectivecrosssectionalstudy AT shonaesquibel theproportionofendometrialtumoursassociatedwithlynchsyndromepetalsaprospectivecrosssectionalstudy AT andrewjwallace theproportionofendometrialtumoursassociatedwithlynchsyndromepetalsaprospectivecrosssectionalstudy AT sanchabunstone theproportionofendometrialtumoursassociatedwithlynchsyndromepetalsaprospectivecrosssectionalstudy AT naomibowers theproportionofendometrialtumoursassociatedwithlynchsyndromepetalsaprospectivecrosssectionalstudy AT ioanaemosneag theproportionofendometrialtumoursassociatedwithlynchsyndromepetalsaprospectivecrosssectionalstudy AT sarahjkitson theproportionofendometrialtumoursassociatedwithlynchsyndromepetalsaprospectivecrosssectionalstudy AT helenaoflynn theproportionofendometrialtumoursassociatedwithlynchsyndromepetalsaprospectivecrosssectionalstudy AT nealcramchander theproportionofendometrialtumoursassociatedwithlynchsyndromepetalsaprospectivecrosssectionalstudy AT vanithansivalingam theproportionofendometrialtumoursassociatedwithlynchsyndromepetalsaprospectivecrosssectionalstudy AT ianmfrayling theproportionofendometrialtumoursassociatedwithlynchsyndromepetalsaprospectivecrosssectionalstudy AT jamesbolton theproportionofendometrialtumoursassociatedwithlynchsyndromepetalsaprospectivecrosssectionalstudy AT rhonajmcvey theproportionofendometrialtumoursassociatedwithlynchsyndromepetalsaprospectivecrosssectionalstudy AT dgarethevans theproportionofendometrialtumoursassociatedwithlynchsyndromepetalsaprospectivecrosssectionalstudy AT emmajcrosbie theproportionofendometrialtumoursassociatedwithlynchsyndromepetalsaprospectivecrosssectionalstudy AT neilajryan proportionofendometrialtumoursassociatedwithlynchsyndromepetalsaprospectivecrosssectionalstudy AT raymondmcmahon proportionofendometrialtumoursassociatedwithlynchsyndromepetalsaprospectivecrosssectionalstudy AT simontobi proportionofendometrialtumoursassociatedwithlynchsyndromepetalsaprospectivecrosssectionalstudy AT tristansnowsill proportionofendometrialtumoursassociatedwithlynchsyndromepetalsaprospectivecrosssectionalstudy AT shonaesquibel proportionofendometrialtumoursassociatedwithlynchsyndromepetalsaprospectivecrosssectionalstudy AT andrewjwallace proportionofendometrialtumoursassociatedwithlynchsyndromepetalsaprospectivecrosssectionalstudy AT sanchabunstone proportionofendometrialtumoursassociatedwithlynchsyndromepetalsaprospectivecrosssectionalstudy AT naomibowers proportionofendometrialtumoursassociatedwithlynchsyndromepetalsaprospectivecrosssectionalstudy AT ioanaemosneag proportionofendometrialtumoursassociatedwithlynchsyndromepetalsaprospectivecrosssectionalstudy AT sarahjkitson proportionofendometrialtumoursassociatedwithlynchsyndromepetalsaprospectivecrosssectionalstudy AT helenaoflynn proportionofendometrialtumoursassociatedwithlynchsyndromepetalsaprospectivecrosssectionalstudy AT nealcramchander proportionofendometrialtumoursassociatedwithlynchsyndromepetalsaprospectivecrosssectionalstudy AT vanithansivalingam proportionofendometrialtumoursassociatedwithlynchsyndromepetalsaprospectivecrosssectionalstudy AT ianmfrayling proportionofendometrialtumoursassociatedwithlynchsyndromepetalsaprospectivecrosssectionalstudy AT jamesbolton proportionofendometrialtumoursassociatedwithlynchsyndromepetalsaprospectivecrosssectionalstudy AT rhonajmcvey proportionofendometrialtumoursassociatedwithlynchsyndromepetalsaprospectivecrosssectionalstudy AT dgarethevans proportionofendometrialtumoursassociatedwithlynchsyndromepetalsaprospectivecrosssectionalstudy AT emmajcrosbie proportionofendometrialtumoursassociatedwithlynchsyndromepetalsaprospectivecrosssectionalstudy |